Related Experiment Video
Updated: May 10, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Drug deprescribing policy and incentives in France
Francis Megerlin1, Gilles Bouvenot2, Patrice Queneau3
1Université de Strasbourg, Strasbourg, France; Académie nationale de pharmacie, Paris, France.
None:
Deprescribing inappropriate drug treatments is a public health issue particularly in countries with a high level of polymedication (polypharmacy). Despite the introduction of the term 'deprescribing' in France in 2002 and the clinical practice guidelines, progress in the outpatient sector has been limited. Our article describes the financial incentives adopted by national agreements between the Assurance Maladie (France's compulsory health insurer scheme) and unions of independent practitioners: pharmacists are encouraged to draw up and share medication reviews (since 2018, target population extended in 2022). As the outcomes have been modest, doctors have then been since 2024 also incentivised to offer medical consultations explicitly dedicated to deprescribing, and to prescribe medication reviews to be drawn up by pharmacists. This article describes the new legal framework for outpatient and inpatient services. It calls for the results expected from 2025 onwards to be measured and studied in national health databases, thanks to the coding associated with these new services.
Related Concept Videos
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Drug Abuse and Addiction: Pharmacological Phenomena
Drug Regulation
Drug Therapy
Antianxiety Medications
Desensitization and Tachyphylaxis
Antidepressant Drugs: MAOIs and Other Agents

